Asset profile
STMC-103H
Microbiome therapeutic
Evidence outlook · lead readout
NCT05003804 · Atopic Dermatitis, Type 1 Hypersensitivity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05003804: The study randomized 283 participants to STMC-103H or placebo with quadruple masking of participants, caregivers, investigators, and outcome assessors. Its primary efficacy endpoint was the clinical outcome of physician-diagnosed atopic dermatitis at day 336, but no primary endpoint results or statistical comparisons have been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.